CompanDX

The collaboration draws on ResearchDx's ability to design, produce, and validate tests, and CompanDx's Distiller platform to deliver small composite biomarker signatures from complex data of high dimensionality.

Under the terms of the multi-year agreement, the partners will advance diagnostic tests, from biomarker discovery to test validation, applying CompanDx's Risk Distiller bioinformatics tool and CRL's CLIA-certified laboratory services.

The partners said they will collaborate on the development of biomarker panels and companion diagnostics for pharmaceutical, biotech, and academic clients worldwide.

The 31-gene signature, used to predict the time to cancer metastasis after initial surgery and biopsy, has been validated by CompanDX researchers in four different datasets, according to the company.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.